Indomethacin
Indomethacin · oral capsule
NSAID
Approved uses
Moderate to severe rheumatoid arthritis (including acute flares), ankylosing spondylitis and osteoarthritis; acute painful shoulder; acute gouty arthritis
25 mg two or three times a day for rheumatoid arthritis, ankylosing spondylitis and osteoarthritis, raised, if well tolerated and symptoms continue, by 25 or 50 mg a day at weekly intervals, to no more than 200 mg a day; 75 mg to 150 mg daily in 3 or 4 divided doses for acute painful shoulder, usually for 7 to 14 days; 50 mg three times a day for acute gouty arthritis until pain is tolerable, then tapered rapidly to stop. Use the lowest effective dosage for the shortest duration
OFF-LABELNot in the FDA label for this product
Non-necrotizing anterior scleritis, diffuse or nodular
25 mg PO QID, the initiating oral regimen reported in the cited review; no fixed course length is given, and the review advises reassessing for escalation if inflammation has not improved after 1 to 2 weeks. The FDA label states that indomethacin is not indicated for long-term treatment and advises periodic eye examinations during prolonged therapy.
Retrospective · no RCTs exist
Retrospective evidence only; there is no randomized trial of any oral NSAID in scleritis. Among 392 patients with noninfectious anterior scleritis at two tertiary centers, NSAIDs were the treatment used in 144 (36.7%), and successful NSAID response was associated with idiopathic diffuse or nodular disease carrying a low degree of scleral inflammation, 2+ or less (OR 2.89, P < 0.001), and with disease free of ocular complications (OR 3.13, P < 0.001), while successful treatment with immunomodulatory therapy was instead associated with necrotizing scleritis (OR 4.73, P = 0.026) and with diffuse or nodular scleritis carrying a systemic association (OR 1.57, P = 0.047).
Contraindications
- Known hypersensitivity, including anaphylactic reactions and serious skin reactions, to indomethacin or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- In the setting of coronary artery bypass graft (CABG) surgery
Indomethacin capsules 25 mg and 50 mg, each in bottles of 30, 100, 500 and 1000 capsules
Has analgesic, anti-inflammatory, and antipyretic properties. Its mechanism of action, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). It is a potent inhibitor of prostaglandin synthesis in vitro, and its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
Warnings & Precautions
- Corneal deposits and retinal disturbances: These, including those of the macula, have been observed in some patients on prolonged therapy, and it is advisable to stop the drug if they appear. Blurred vision warrants a thorough eye examination, and because the changes may cause no symptoms, periodic eye examinations are advisable on prolonged therapy. Indomethacin is not indicated for long-term treatment.
- Cardiovascular thrombotic events: NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. The risk may occur early in treatment and may increase with duration of use. Indomethacin is contraindicated in the setting of CABG surgery. Avoid use in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events.
- Gastrointestinal bleeding, ulceration and perforation: NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk. If a serious GI adverse event is suspected, discontinue indomethacin until it is ruled out.
- Hepatotoxicity: Rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure, have been reported. Inform patients of the warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.
- Hypertension: NSAIDs can lead to new onset of hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.
- Heart failure and edema: Fluid retention and edema have been observed in some patients treated with NSAIDs. Avoid use in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.
- Renal toxicity and hyperkalemia: Long-term NSAID use has resulted in renal papillary necrosis and other renal injury. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use in advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. Indomethacin and triamterene should not be administered together. Hyperkalemia has been reported, even in some patients without renal impairment.
- Anaphylactic reactions: Indomethacin has been associated with anaphylactic reactions in patients with and without known hypersensitivity to indomethacin and in patients with aspirin-sensitive asthma. Seek emergency help if an anaphylactic reaction occurs.
- Exacerbation of asthma related to aspirin sensitivity: Contraindicated, because cross-reactivity between aspirin and other NSAIDs has been reported. In preexisting asthma without known aspirin sensitivity, monitor for changes in asthma signs and symptoms.
- Serious skin reactions: NSAIDs, including indomethacin, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal, and can also cause fixed drug eruption (FDE). These serious events may occur without warning. Discontinue at first appearance of skin rash or other signs of hypersensitivity.
- Drug reaction with eosinophilia and systemic symptoms (DRESS): DRESS has been reported in patients taking NSAIDs, and some of these events have been fatal or life-threatening. Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue indomethacin and evaluate the patient immediately.
- Fetal toxicity: Avoid use at about 30 weeks gestation and later, because of the risk of premature closure of the fetal ductus arteriosus. Use at about 20 weeks gestation or later may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. If needed between about 20 and 30 weeks, limit use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid beyond 48 hours of use, and discontinue if oligohydramnios occurs.
- Hematologic toxicity: Anemia has occurred in NSAID-treated patients, and NSAIDs may increase the risk of bleeding events. Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. Co-morbid conditions, such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents, SSRIs or SNRIs, may increase the bleeding risk, so monitor these patients for signs of bleeding.
- Masking of inflammation and fever: Reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.
- Laboratory monitoring: Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically.
- Aggravated depression, epilepsy and parkinsonism: indomethacin may aggravate depression or other psychiatric disturbances, epilepsy and parkinsonism, so use considerable caution in these patients, and stop it if severe CNS reactions develop. It may cause drowsiness, so caution patients about activities requiring mental alertness and motor coordination, such as driving a car. Headache that persists despite a dose reduction requires stopping indomethacin.
Common Side Effects
The most common adverse reactions, at an incidence of 3% or more, are headache, dizziness, dyspepsia and nausea.
Pregnancy: NSAIDs can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment, so limit dose and duration of use between about 20 and 30 weeks of gestation and avoid use at about 30 weeks of gestation and later in pregnancy.
Lactation: Based on available published clinical data, indomethacin may be present in human milk, so weigh the benefits of breastfeeding against the mother's clinical need and any potential adverse effects on the breastfed infant.
Safety and effectiveness are not established at 14 years and younger, and it should not be prescribed at those ages unless toxicity or lack of efficacy of other drugs warrants the risk. If it is used from age 2, monitor closely with periodic liver function tests, because hepatotoxicity, including deaths, has been reported in juvenile rheumatoid arthritis. Suggested start 1 to 2 mg/kg/day in divided doses, not to exceed 3 mg/kg/day or 150 to 200 mg/day, whichever is less.